Academic Journals Database
Disseminating quality controlled scientific knowledge

Aligning the Economic Value of Companion Diagnostics and Stratified Medicines

ADD TO MY LIST
 
Author(s): Edward D. Blair | Elyse K. Stratton | Martina Kaufmann

Journal: Journal of Personalized Medicine
ISSN 2075-4426

Volume: 2;
Issue: 4;
Start page: 257;
Date: 2012;
Original page

Keywords: stratified medicines | economic value | health outcomes | multiple stakeholders | companion diagnostic | regulation | reimbursement

ABSTRACT
The twin forces of payors seeking fair pricing and the rising costs of developing new medicines has driven a closer relationship between pharmaceutical companies and diagnostics companies, because stratified medicines, guided by companion diagnostics, offer better commercial, as well as clinical, outcomes. Stratified medicines have created clinical success and provided rapid product approvals, particularly in oncology, and indeed have changed the dynamic between drug and diagnostic developers. The commercial payback for such partnerships offered by stratified medicines has been less well articulated, but this has shifted as the benefits in risk management, pricing and value creation for all stakeholders become clearer. In this larger healthcare setting, stratified medicine provides both physicians and patients with greater insight on the disease and provides rationale for providers to understand cost-effectiveness of treatment. This article considers how the economic value of stratified medicine relationships can be recognized and translated into better outcomes for all healthcare stakeholders.
Save time & money - Smart Internet Solutions     

Tango Rapperswil
Tango Rapperswil